[8-K] CorMedix Inc. Reports Material Event

Rhea-AI Filing Summary

On 23 June 2025, CorMedix Inc. (CRMD) filed a Form 8-K under Item 7.01 (Regulation FD). The company disclosed that it had released a press release (attached as Exhibit 99.1) providing an update on its Large Dialysis Organization (LDO) customer and confirmed that implementation is planned for the second half of 2025. No financial metrics, contractual terms, or quantitative guidance were included in the filing. Because the information is being furnished, not filed, it is exempt from Section 18 liability and will not be automatically incorporated into other SEC filings unless specifically referenced.

Insights

Financial Analyst

TL;DR: Routine Reg FD 8-K; only timeline update, no financials—minimal immediate impact.

The 8-K simply furnishes a press release noting progress with CorMedix’s LDO customer and a targeted rollout in H2 2025. There are no revenue projections, contract values, or margin implications disclosed, limiting investors’ ability to reassess valuation. Because the item is furnished, management preserves flexibility without incurring Section 18 liability. Overall, the disclosure signals ongoing operational execution but lacks material financial detail, rendering the near-term market impact neutral.

Corporate Disclosure Specialist

TL;DR: Standard Item 7.01 filing—informational, non-binding, low governance risk.

Management used Item 7.01 to share a business update outside of the formal ‘filed’ channels, an accepted practice when the data is non-financial. The decision not to file under Items 1.01 or 8.01 suggests no definitive agreement or material event arose. Compliance is satisfactory: exhibits are properly indexed, and the inline XBRL cover has been provided. From a disclosure standpoint, the content is routine and should not alter risk assessments.

false 0001410098 0001410098 2025-06-23 2025-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

CORMEDIX INC.

(Exact name of registrant as specified in its charter)

Delaware		001-34673		20-5894890
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

300 Connell Drive, Suite 4200 Berkeley Heights, NJ		07922
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (908) 517-9500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2, below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		CRMD		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 23, 2025, the Company issued a press release announcing an update related to its Large Dialysis Organization customer and planned implementation in the second half of 2025, a copy of which is attached hereto as Exhibit 99.1.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated June 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CORMEDIX INC.
Date: June 23, 2025	By:	/s/ Joseph Todisco
	Name:	Joseph Todisco
	Title:	Chief Executive Officer

2

FAQ

What did CorMedix (CRMD) announce in its June 23 2025 Form 8-K?

The company furnished a press release updating progress with a Large Dialysis Organization customer and confirmed rollout in H2 2025.

Does the 8-K include any financial results or earnings guidance for CorMedix?

No. The filing contains no revenue figures, earnings data, or guidance.

How is the information in Item 7.01 treated under SEC rules?

It is "furnished" rather than "filed," so it is not subject to Section 18 liability and won’t be incorporated into other filings unless cited.

When is the planned implementation with the Large Dialysis Organization customer?

The company targets the second half of 2025.

Where can investors find the detailed press release referenced in the 8-K?

It is attached as Exhibit 99.1 to the Form 8-K filing.